Alliance Wealth Advisors LLC UT Buys 2,938 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Alliance Wealth Advisors LLC UT raised its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 14.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 23,992 shares of the biopharmaceutical company’s stock after buying an additional 2,938 shares during the period. Alliance Wealth Advisors LLC UT’s holdings in Gilead Sciences were worth $1,944,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Tompkins Financial Corp boosted its stake in Gilead Sciences by 223.1% in the third quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 241 shares during the last quarter. OFI Invest Asset Management acquired a new position in shares of Gilead Sciences in the 3rd quarter valued at $26,000. Fortitude Family Office LLC bought a new position in shares of Gilead Sciences in the 4th quarter worth $29,000. Rakuten Securities Inc. acquired a new stake in shares of Gilead Sciences during the fourth quarter worth $33,000. Finally, Financial Connections Group Inc. acquired a new stake in shares of Gilead Sciences during the fourth quarter worth $40,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

GILD has been the subject of a number of analyst reports. Morgan Stanley decreased their price objective on Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating for the company in a research note on Friday. Royal Bank of Canada decreased their target price on Gilead Sciences from $76.00 to $74.00 and set a “sector perform” rating for the company in a research note on Friday. UBS Group decreased their target price on Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating for the company in a research note on Wednesday, April 17th. Mizuho decreased their target price on Gilead Sciences from $101.00 to $90.00 and set a “buy” rating for the company in a research note on Thursday, February 22nd. Finally, Oppenheimer reissued an “outperform” rating and issued a $105.00 target price on shares of Gilead Sciences in a research note on Friday, April 19th. Eleven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Gilead Sciences currently has a consensus rating of “Hold” and an average target price of $83.87.

Insider Buying and Selling

In related news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $72.96, for a total transaction of $145,920.00. Following the sale, the insider now owns 96,304 shares of the company’s stock, valued at $7,026,339.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.16% of the stock is currently owned by company insiders.

Gilead Sciences Stock Performance

NASDAQ:GILD traded up $0.15 on Friday, hitting $65.42. The company’s stock had a trading volume of 12,382,425 shares, compared to its average volume of 6,443,315. The company has a current ratio of 1.43, a quick ratio of 1.27 and a debt-to-equity ratio of 1.08. The stock has a fifty day moving average of $71.28 and a two-hundred day moving average of $76.25. The firm has a market capitalization of $81.45 billion, a P/E ratio of 181.72, a price-to-earnings-growth ratio of 1.17 and a beta of 0.19. Gilead Sciences, Inc. has a one year low of $64.63 and a one year high of $87.86.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.49) by $0.17. The company had revenue of $6.69 billion for the quarter, compared to analyst estimates of $6.36 billion. Gilead Sciences had a return on equity of 23.08% and a net margin of 1.76%. The firm’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same quarter last year, the company earned $1.37 earnings per share. Research analysts predict that Gilead Sciences, Inc. will post 4.2 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 27th. Investors of record on Friday, June 14th will be given a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a yield of 4.71%. The ex-dividend date is Friday, June 14th. Gilead Sciences’s dividend payout ratio is currently 855.56%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.